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Daniel Żakowiecki, Kinga Hyla, Bartłomiej Milanowski, Kajetan Koperwas, Kamil Kaminśki,
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ABSTRACT: In this paper, several experimental techniques [X-ray diffraction,
differential scanning calorimetry (DSC), thermogravimetry, Fourier transform infrared
spectroscopy, and broad-band dielectric spectroscopy] have been applied to
characterize the structural and thermal properties, H-bonding pattern, and molecular
dynamics of amorphous bosentan (BOS) obtained by vitrification and cryomilling of
the monohydrate crystalline form of this drug. Samples prepared by these two methods
were found to be similar with regard to their internal structure, H-bonding scheme, and
structural (α) dynamics in the supercooled liquid state. However, based on the analysis
of α-relaxation times (dielectric measurements) predicted for temperatures below the
glass-transition temperature (Tg), as well as DSC thermograms, it was concluded that
the cryoground sample is more aged (and probably more physically stable) compared
to the vitrified one. Interestingly, such differences in physical properties turned out to
be reflected in the lower intrinsic dissolution rate of BOS obtained by cryomilling (in
the first 15 min of dissolution test) in comparison to the vitrified drug. Furthermore, we showed that cryogrinding of the crystalline
BOS monohydrate leads to the formation of a nearly anhydrous amorphous sample. This finding, different from that reported by
Megarry et al. [Carbohydr. Res. 2011, 346, 1061−1064] for trehalose (TRE), was revealed on the basis of infrared and thermal
measurements. Finally, two various hypotheses explaining water removal upon cryomilling have been discussed in the manuscript.
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■ INTRODUCTION
Over the years, the pharmaceutical industry developed a
number of approaches that led to the increase of the solubility,
dissolution rate, and ultimately bioavailability of poorly water-
soluble drugs from solid dosage forms. It turned out that the
most common and efficient way to enhance these important
properties is the chemical transformation of the active
pharmaceutical ingredient (API) into its salt.1 Unfortunately,
only about 20−30% of the new potential API molecules may
undergo such chemical conversion. Therefore, other methods
are being sought to modify the solubility of the remaining 70−
80% of pharmaceuticals.2 Herein, one can list the most popular
ones, including the formation of solid lipid nanoparticles,3
liposomes,4 micelles,5 soft gelatine capsules,6 co-crystals,7 or
metastable polymorphs.8 Simultaneously, in recent years, a
change of the physical state of the sample, i.e., amorphization,
has attracted increasing attention of scientists working in this
field.9−13
In general, amorphous APIs can be obtained via methods
based on mechanical activation of a crystalline mass (e.g.,
during milling/grinding),14−18 solvent removal (e.g., freeze- or
spray-drying),10,19−23 and temperature variation (e.g., vitri-
fication).24,25 Each of them has its advantages and disadvan-
tages. Regarding the temperature-based methods, the amor-
phous form of the desired active substance is made by the fast
cooling of the melt. In recent years, this approach has been
gaining increasing interest, especially considering the extru-
sion-based production techniques (e.g., hot melt extrusion).
However, it has a certain limitation. Namely, it is not suitable
for compounds undergoing thermal degradation at the melting
point.26,27 There are also systems very sensitive to solvents.28,29
In such cases, methods involving mechanical activation of
crystalline material using various types of mills seem to be a
quite interesting alternative. Intensive studies on this topic by
Descamps’ group revealed that the balance between the
temperature of milling and the glass-transition temperature
(Tg) of API plays a crucial role in the effectiveness of
amorphization.30−32 They have shown that when the process is
carried out at temperatures (T) significantly below Tg (e.g.,
grinding in a liquid nitrogen atmospherecryomilling),
amorphization is promoted. If T are close or above the Tg of
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the sample (e.g., room temperature), the material undergoes
polymorphic transformations.33,34 More importantly, in some
cases, milling allows for the production of metastable
polymorphs not achievable by other methods.27,33,35,36
However, even this preparation technique has its limitations.
Namely, the physical stability of the amorphous substance
obtained via grinding of the crystalline solid might differ
significantly from that produced by rapid cooling of a molten
sample. Such a situation occurred in indomethacin, where the
amorphous substance prepared by grinding recrystallized over
1000 times faster than the one obtained by vitrification.27,37
Moreover, even if milling is one of the most effective ways to
lower the activation barrier for different types of chemical
reactions (tribochemistry),38 many substances undergo
decomposition during this process.39 To avoid this undesired
effect, very often, the temperature of the milling is lowered
(cryomilling/cryogrinding).40 However, it should be pointed
out that there is a reported case of the APIfurosemide
which undergoes chemical decomposition during cryogenic
grinding alone as well as in the system with inulin or
poly(vinylpyrrolidone) (PVP) polymer.41 It was clearly shown
that the character of the excipient has a tremendous impact on
the progress of chemical decomposition of this popular
diuretic. Herein, one can stress that the presence of substances
forming hydrogen bonds (e.g., inulin or PVP) catalyzed this
process, while those characterized by van der Waals
interactions (acetylated saccharides) stabilized API (inhibited
its dissociation).42 Therefore, a better understanding of the
nature of the amorphous materials obtained by milling seems
to be of fundamental importance.
Based on the reported data, one can distinguish several main
ideas explaining the crystalline-to-amorphous transformation
upon mechanical grinding.43−47 The most popular concept
proposed by Martin and Bellon explains the mutual depend-
ence between the temperature of grinding and the effectiveness
of amorphization.44 The authors postulated that the crystalline-
to-amorphous transition is a result of two competing
processes: a disordering process induced by milling (thermally
independent) and a recovery process (thermally dependent).
Another approach suggests that amorphization might be
understood as a milling-induced disorder generated by a
large number of mechanical perturbations (reduction of
crystallite size, accumulation of crystallite defects, polymorphic
transformations, and partial or complete amorphization).46,47
Researchers indicate that during grinding, the progressive
defects in the crystalline lattice increase the overall energy of
the system, which, in turn, constitutes the necessary
thermodynamic-driven force to initiate the transformation.43
Finally, it is also worth mentioning the concept considering the
local heating effect. It assumes that the release of energy during
a mechanical impact leads to the local heating of the sample,
which is instantaneously cooled very fast. Herein, it should be
noted that intensive studies by Descamps’ group on the
progress of mutarotation in milled lactose and glucose
indicated that this idea is not reliable.35,48
In this paper, we present the comparative analysis of the
amorphous bosentan (BOS) obtained by both vitrification and
cryomilling of the crystalline monohydrate form of this API.
Bosentan (BOS) is an endothelin-1 receptor antagonist
dedicated for the treatment of pulmonary arterial hypertension
(PAH) in adults. It decreases both systemic vascular resistance
and pulmonary vascular resistance, and consequently increases
cardiac output without increasing the heart rate.16,49 Due to
the fact that BOS is poorly soluble in water and a highly
permeable compound, it is classified as a class IIa drug within
the Biopharmaceutical Classification System (BCS). Amorph-
ization, therefore, seems like a sound step in the enhancement
of its solubility/dissolution rate. Herein, we confirmed that one
is able to obtain BOS with a negligible water content as a result
of cryomilling. Furthermore, we found out that regardless of
the chosen method of amorphization (vitrification or
cryogrinding), the samples are nearly identical in terms of
the local structure and H-bonding scheme. However, they
differ significantly with respect to their dynamical properties
below the Tg, as well as in dissolution rates with respect to the
crystalline form of API.
■ EXPERIMENTAL SECTION
Materials and Methods. Material. Bosentan monohy-
drate of molecular weight MW = 569.6 g mol
−1 and purity ≥
99% was donated by Polpharma (Starogard Gdanśki, Poland)
and used without further purification. Its chemical structure is
presented in Scheme 1.
Preparation of Amorphous Samples. Preparation of the
vitrified system in the case of calorimetric measurements was
done by melting of the crystalline bosentan monohydrate at T
= 500 Kduring the first differential scanning calorimetry
(DSC) scanand vitrification by fast cooling (20 K min−1)
during the second DSC scan. Sample preparation for the X-ray
diffraction (XRD), Fourier transform infrared spectroscopy
(FTIR), and broad-band dielectric spectroscopy (BDS) studies
involved melting at T = 500 K, followed by vitrification on a
previously chilled copper plate. All measurements were
performed immediately after preparation of the amorphous
systems to avoid recrystallization.
Grinding was carried out using a cryogenic impact mill
(CryoMill ∼100−240 V-50/60 Hz, Retsch GmbH, Germany)
consisting of a stainless steel vessel immersed in liquid
nitrogen, within which a stainless steel rod is vibrated by
means of a magnetic coil. Before grinding, a 5 min precool time
was programmed. Then, the mill was planned to have an
impact frequency of 9 cycles per second for 12 min grinding
periods separated by 3 min cool−down periods. The total
milling time for our sample was 2.5 h. After this time, the
grinding vial was opened and the sample was immediately
transferred for thermogravimetric analysis (TGA) and DSC
investigations. The freshly prepared cryomilled BOS was a
yellow powder.
X-ray Diffraction (XRD). XRD measurements were
performed on a Rigaku-Denki D/MAX RAPID II-R diffrac-
tometer equipped with an image plate detector, a rotating Ag
anode, and an incident beam (002) graphite monochromator
Scheme 1. Chemical Structure of BOS Monohydrate
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(wavelength of the incident beam λ = 0.56 Å). Samples were
measured in borosilicate glass capillaries, in the Debye−
Scherrer geometry. The diffraction data were collected as two-
dimensional patterns and converted into one-dimensional
functions of scattering intensity versus scattering angle 2θ.
Finally, the background intensity from the empty capillary was
subtracted.
Differential Scanning Calorimetry (DSC). The thermody-
namic properties of BOS samples were examined using a
Mettler Toledo DSC 1 STARe System (Columbus, OH). The
measuring device was equipped with an HSS8 ceramic sensor
having 120 thermocouples. The instrument was calibrated for
temperature and enthalpy using indium and zinc standards.
The melting points were determined as the onset of the peak,
whereas the glass-transition temperatures were determined as
the midpoint of the heat capacity increment. The samples were
placed in aluminum crucibles (40 μL). All measurements were
carried out in the range of 300−500 K with a 10 K min−1
heating rate.
Thermogravimetric Analysis (TGA). Water evaporation
from BOS (crystalline and cryomilled samples) was examined
by a Mettler TG 50 thermogravimetric analyzer linked to a
Mettler MT5 balance (Mettler Toledo, Switzerland). The
powder in open aluminum pans was placed in a furnace under
nitrogen purge (30 mL min−1) and heated at 10 K min−1 from
room temperature to T = 1150 K. Water evaporation of the
sample was determined by the weight loss percentage.
Fourier Transform Infrared (FTIR) Spectroscopy. FTIR
spectra of the crystalline BOS monohydrate, as well as vitrified
and cryomilled API, were collected in attenuated total
reflectance (ATR) mode using a Thermo Scientific Nicolet
iS50 spectrometer equipped with a built-in ATR accessory.
The samples were placed on the ATR crystal and measured at
a resolution of 4 cm−1 in the wavenumber range of 400−4000
cm−1. Baseline corrections were performed using OMNIC
software.
Broad-Band Dielectric Spectroscopy (BDS). Dielectric
measurements of the amorphous (vitrified and cryomilled)
BOS were carried out using Novo-Control GMBH Alpha
dielectric spectrometer (Montabaur, Germany), in the
frequency range of 10−1−106 Hz, at given temperatures, with
a heating rate equal to 0.5 K min−1. The temperature was
controlled by a Quatro temperature controller with temper-
ature stability better than 0.1 K. The samples were placed in a
parallel-plate cell made of stainless steel (diameter 15 mm, and
0.1 mm gap with quartz spacer).
Intrinsic Dissolution Testing. The intrinsic dissolution rate
(IDR) of the crystalline, cryomilled, and vitrified BOS samples
was measured by the stationary disc system50 using an Erweka
DT60 paddle dissolution testing apparatus (ERWEKA GmbH,
Germany). About 100 mg of API was compressed at 1500 psi
and held for 60 s in a die to form compacted disks of 8 nm
diameters and the same thickness (to eliminate the effect of
different specific areas of both materials). Dissolution studies
were performed in 500 mL of 1% w/v sodium dodecyl sulfate
(SDS) in ultrapure water51 maintained at 37 ± 0.5 °C and a
paddle rotation speed of 100 rpm. They were carried out for
120 min, and the concentration of API was determined on-line
every 5 min by a UV−vis spectrophotometer Nicolet Evolution
300 (Thermo Electron Corporation) at 264 nm (signal) and
450 nm (background correction). All measurements were
performed in triplicate. IDR, the rate of mass transfer from
solid to liquid state, when conditions such as surface area, pH,
ionic strength, and stirring speed are kept constant, was




where C is the drug concentration at time t, V is the volume of
the test solution, S is the disk’s surface area, k is the intrinsic
dissolution rate constant, and Cs is the saturation solubility of
the drug. The IDRs were calculated from each curve’s slope for
periods of 0−120 min for crystalline BOS, and 0−15 and 60−
120 min for vitrified and cryomilled BOS, respectively.
■ RESULTS AND DISCUSSION
At the beginning of the study, we prepared amorphous BOS
systems employing two methods: cryomilling and vitrification.
To determine whether the samples were fully amorphous after
processing, XRD measurements were carried out. In Figure 1A,
XRD patterns of the studied crystalline BOS monohydrate and
its reference from the Cambridge Crystallographic Data Centre
(CCDC, no. 920210) are overlapped (wine and black lines,
respectively). The XRD data in a wider 2θ range are presented
in the Supporting Information (Figure S1). The agreement
between both XRD patterns confirms that the initial crystalline
BOS has a monohydrate form. According to literature data,
this BOS monohydrate crystallizes in the monoclinic P21/c
system (unit cell parameters: 12.3393(4), 15.1238(6),
14.6988(4) Å, unit cell angles: 90.0, 95.037(3), 90.00°) with
four molecules per unit cell.53 Figure 1B,C shows XRD data for
the amorphous BOS produced by vitrification and cryomilling
(light red and blue lines, respectively). It can be seen that the
XRD patterns are typical for the disordered structures with no
long-range crystalline order. That means both methods were
successfully used to amorphization of BOS monohydrate.
However, one can see that the shape of the XRD patterns for
disordered API resembles the broadened pattern of the
crystalline sample, indicating that the main structural motif
of the local structure of the crystalline form may be preserved
Figure 1. X-ray diffraction patterns of (A) crystalline BOS monohydrate and its reference from CCDC database, (B) vitrified BOS just after
preparation and after 1 month of storage, and (C) cryomilled BOS just after preparation and after 1 month of storage.
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in the amorphous phase. The pre-peak appearing in the XRD
patterns of the disordered samples around 3.2° before the main
diffraction peak is the fingerprint of the supramolecular
structure. It signifies the presence of supramolecular assemblies
and the medium-range order in the amorphous BOS. However,
since the applied vitrification and cryomilling caused a
transformation of the molecular structure from crystalline
toward more disordered, we will refer to them as “amorphous”
samples.
A comparison of the diffractograms for the vitrified and
cryomilled API (Figure 1B,C) exhibits that they are very
similar. The diffraction data normalized to unity are
characterized by almost identical peak positions, widths, and
intensities. Moreover, the atomic pair distribution functions of
the studied materials, shown in Figure S2 in the Supporting
Information, are almost identical at both short- and medium-
range scales. Hence, one can state that the atomic-scale
structures of both samples are very similar. Moreover, after 1
month of storage at room temperature (relative humidity
ranging between 40 and 50%) and under ambient pressure, the
diffraction patterns of vitrified and cryomilled BOS did not
show any changes compared to those collected immediately
after preparation (see the solid and dotted lines in Figure
1B,C).
The described similarities between the amorphous BOS
samples, especially the ones indicating the presence of
supramolecular structures, raise the question whether there is
water in the cryoground sample that should have some impact
on the spatial rearrangement of the molecules. To test this
hypothesis and characterize the amorphous BOS samples
prepared via vitrification and cryomilling in more detail, we
performed studies with the use of DSC, thermogravimetry, and
FTIR methods.
First, the thermal properties of crystalline bosentan (BOS)
monohydrate, as well as two amorphous samples, were
determined. The thermograms obtained from DSC measure-
ments carried out in the temperature range of 300−500 K with
a heating rate of 10 K min−1 are presented in Figure 2A. It can
be seen that the crystalline sample (wine line in the inset)
exhibits an endothermal peak, which is not singularthere is
an additional trailing edge to it. Such behavior results from the
overlapping of two processes: the melting of the sample with
the onset at 379 K and the evaporation of the hydration water.
On the other hand, DSC curves of the vitrified (light red line)
as well as cryomilled (light blue line) substances are
characterized by the presence of a single step-like thermal
event that corresponds to the glass transition. The exact values
of the Tg’s are similar and equal to 353 and 355 K for the BOS
samples obtained by melt quenching and cryomilling,
respectively. Importantly, the increase in the enthalpy recovery
is much stronger for the cryomilled sample in comparison to
the vitrified one. According to the literature data, such a great
overshoot in enthalpy in the former sample indicates that it
exhibits the characteristics of material aged for a long time. A
similar scenario was observed for amber glass aged for billion
years.54 Hence, one can state that the amorphous API obtained
by cryomilling is more aged with respect to the vitrified one.
Moreover, both amorphous samples did not show any
tendency toward recrystallization during the nonisothermal
calorimetric studies. Furthermore, the absence of melting peaks
can be taken as further evidence that both methods of
preparation (vitrification and cryomilling) ensure fully
amorphous BOS.
As complementary to DSC, thermogravimetric measure-
ments were carried out on the crystalline and cryoground BOS.
TGA curves of both samples are presented in Figure 2B (solid
wine and light blue line, respectively). During this experiment,
two weight loss steps were observed in each case: the first, a
loss of almost 3.3 wt % (crystalline monohydrate) or 0.7 wt
%endothermal peak near 300−320 K (cryoground sub-
stance), which can be identified as water evaporation, and the
second with an onset at approximately 600 K, corresponding to
thermal decomposition of the sample. Note that the water
removal during melting of the crystalline BOS monohydrate is
in good agreement with the literature.55 Importantly, a weight
loss of approximately 0.7 wt % indicates a strongly reduced
water content compared to the crystalline BOS (weight loss 3.3
wt %). It means that its large amount has been removed from
Figure 2. (A) DSC thermograms of cryomilled and vitrified BOS and (inset) crystalline BOS monohydrate. (B) TGA trace of crystalline and
cryomilled BOS samples.
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the cryomilled sample (note that the residual water molecules
are located between API molecules). To confirm this
experimental observation as well as to check whether the H-
bonding scheme is the same in both amorphous BOS systems,
we performed further FTIR investigations. The infrared
spectrum of the crystalline BOS, commercially available in
the form of monohydrate (BOS·H2O), was also measured for
comparison. Figure 3A,B illustrates the representative FTIR
spectra of these three samples obtained in the two frequency
ranges, 3800−2400 cm−1 and 1700−450 cm−1, respectively.
Moreover, the detailed FTIR bands’ assignments of crystalline
BOS·H2O, correlated with DFT calculations, are presented in
the Supporting Information. It is clearly visible that FTIR
spectra of amorphous BOS prepared by the two methods (light
blue and light red lines in Figure 3A,B) resemble that of the
crystalline sample, especially in the lower-frequency range
(below 1700 cm−1). However, both samples have broader
peaks than the crystalline one, and the peak splitting partially
disappears in these systems. It means the destruction of long-
range crystalline order after vitrification as well as cryomilling
of BOS monohydrate. The noticeable spectral differences
between the analyzed spectra can be found in the regions
associated with the formation of H-bonds, i.e., 3700−2400 and
1620−1520 cm−1. In the disordered BOS, the X−H band
contour (3550−3200 cm−1) changes and the peak at 3626
cm−1 (assigned to the vibrations of water in the collected
spectra) disappears. Moreover, the shoulder occurring between
3000 and 2400 cm−1 is not detected for amorphous samples.
These experimental results are evidence of a reorganization of
the H-bond network of API and the resulting variations in the
geometrical parameters of the X−H bonds, as the water
content is strongly reduced. In this place, one can notice that
the spectral profiles of amorphous BOS obtained via two
various methods are nearly the same. It indicates a similar H-
bonding scheme in these systems and much different with
respect to the crystalline API.
Hence, FTIR data are consistent with the outcome of the
TGA investigations that revealed a significantly lower amount
of water in the cryoground amorphous BOS with respect to the
crystalline BOS monohydrate.
Importantly, this striking and intriguing result is different
from that reported by Megarry et al. for trehalose (TRE),
which is however not a hydrophobic, but a hydrophilic
sample.56 In the recalled work, the authors postulated that
cryogenic milling is the only method to obtain hydrated
amorphous substances. Just to mention that due to cryomilling
of the crystalline trehalose (TRE) dihydrate, they always
obtained a hydrated disordered sample. Therefore, a few
important questions arise. Why the result described by us and
the one reported by Megarry et al. are so different? From the
analysis of the chemical structure of BOS and TRE as well as
their solubility in water, we can easily find that the former
system is more hydrophobic and almost insoluble in this
solvent, while TRE has plenty of hydroxyl units capable of
forming strong intermolecular HBs in aqueous solutions
(consequently, it dissolves in water very well). In fact, one
can postulate that the hydrophobic character of BOS underlies
water removal from the sample. However, in addition, there
must be other factors responsible for the water disappearance/
evaporation. Based on the diffractograms and FTIR spectra
indicating the same local structure and H-bonding interaction
pattern of the cryomilled and vitrified BOS, one can speculate
that upon cryogrinding, local heating of the sample around T ∼
393 K occurs. This process is followed by instantaneous
quenching. However, if this hypothesis is true, the water
removal should be detected also in the case of cryoground
trehalose dihydrate since the melting temperature of hydrated
saccharide is comparable to that of BOS monohydrate.
Figure 3. FTIR spectra of the crystalline BOS monohydrate (wine line), amorphous BOS produced via vitrification (light red line), and cryomilling
(light blue line). The data are presented in two spectral regions: (left) 3800−2400 cm−1 and (right) 1700−450 cm−1. The spectra were normalized
with respect to the absorbance maximum in the selected frequency ranges and plotted with an offset for clarity.
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Therefore, it seems that this explanation does not hold
anymore. Hence, to explain the differences between our data
and those reported earlier by Megarry et al.,56 one can take
into account the hermeticity of the vessel. In the case of our
investigations, a vial that is hermetically closed at T = 298 K
and then cooled down to T ∼ 80 K was used. Such a dramatic
decrease in temperature is surely accompanied by a drop in
pressure inside the vessel. However, it is not as significant as in
the case of the ordinary freeze-drying process. Next, due to
water release from the crystalline lattice during milling, it
solidifies as ice, and then it is removed via sublimation, just as
it happens during lyophilization. Importantly, this effect most
likely can be observed only in the mills, where the vessel is
hermetically closed (RETSCH Mill). In other cases, such a
phenomenon may not be detected. However, it is just a
hypothesis that must be verified experimentally in the future by
investigating other hydrates in different kinds of grinders. It is
worth to stress that at the moment, we have no other
reasonable explanation on the water removal upon cryogrind-
ing of the examined API.
As the following step, we decided to apply dielectric
spectroscopy to assess the molecular mobility of amorphous
BOS prepared via different techniques. Taking into consid-
eration the results provided from thermogravimetric and
infrared studies, that both amorphization methods result in
nearly/fully anhydrous BOS, one can exclude the impact of
water on the molecular dynamics both above and below
samples’ Tgs. During the heating of the vitrified and cryomilled
API (the direction of BDS experiments was from low T to high
T), one can observe a well-resolved peak in dielectric spectra
corresponding to the structural (α) relaxation process; see
Figure 4A,B. This peak is well visible at temperatures above
357 K (i.e., in the supercooled liquid region) and moves
toward higher frequencies with increasing temperature. We
fitted the selected α-loss peak for each sample ( fmax ∼ 10 Hz)
by means of the one-sided Fourier transform of the
Kohlrausch−Williams−Watts (KWW) function to characterize
its shape;57,58 see Figure 4C (black line). It should be
emphasized that the value of the βKWW parameter (T ∼ Tg) is
the same, equal to 0.62, regardless of the amorphization
method. Furthermore, we found that the shape of the α-loss
peak is nearly insensitive to temperature change (see Figure S5
in the Supporting Information). It is worth mentioning that
βKWW might vary from 0 to 1. If this parameter is approaching
0, the shape of the structural relaxation is asymmetric and
broad. However, if the value of βKWW is equal to 1, it means
that the α-relaxation peak is symmetric and narrow, which
corresponds to the Debye case. BOS having βKWW = 0.62 and
Δεα = 7.8, similarly to the case of celecoxib (βKWW = 0.67, Δεα
= 8.3),59 eugenol (βKWW = 0.68, Δεα = 8.0),60 and 2-phenyl-5-
acetomethyl-5-ethyl-1,3-dioxocyclohexane (βKWW = 0.64, Δεα
= 8.0),61 follows the anticorrelation between the narrowness of
α-loss peak (high value of βKWW) and its dielectric strength
(Δεα) in the van der Waals glass formers.62 Note that the Δεα
parameter for the examined API was determined from the
analysis of loss spectra recorded above the Tg using the
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Figure 4. (A, B) Representative dielectric loss spectra of amorphous BOS above its glass-transition temperature. Light red lines correspond to the
vitrified sample, while light blue lines correspond to the cryomilled one. Solid green lines through the points (open circles) are HN fits to the
spectra measured at 369 and 367 K, respectively. (C) Comparison of the shape of α-process in the vicinity of Tg (for the same τα). The black line
represents KWW fit. (D) Relaxation map of BOS. Red and blue pentagons correspond to the vitrified and cryomilled samples. The temperature
dependence of structural relaxation times, τα, in the supercooled liquid state has been described by the VFT equation (solid gray lines).
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where ε0 is the permittivity of vacuum, σDC is the direct current
(dc) conductivity, ω is equal to 2πf (where f is the frequency of
the maximum of the peak), τHN is the HN relaxation time, a
and b are the parameters that represent the symmetric and
asymmetric broadening of the relaxation peak, respectively
(representative fits of the HN function to the dielectric spectra
are presented in Figure 4A,Bgreen lines). From the
mentioned fitting procedure, we also determined the depend-
encies of α-relaxation times (τα) in a broad temperature range
for the vitrified and cryomilled API systems. It should be added
that τα, recalculated from τHN according to the following
formula (eq 3)63






































is presented in Figure 4D as light red and blue pentagons. The
temperature evolution of structural relaxation times usually
shows non-Arrhenius-like behavior in the supercooled liquid
region. Therefore, to parameterize it, we applied the Vogel−














where τ∞, B, and T0 are fitting parameters. To determine the
values of Tg, a well-known definition, where Tg = T (τα = 100
s) was used. Accordingly, from the extrapolation of VFT fit to
100 s, we estimated Tg of both vitrified and cryomilled samples
as 351 K. Note that the obtained value was close to those
determined from DSC studies (353 and 355 K, respectively)
considering the different heating rates applied during the
measurements.67 Furthermore, both presented τα(T) depend-
encies are in very good agreement, which implies that
regardless of the preparation method, amorphous BOS exhibits
the same structural dynamics in the supercooled liquid state.
As reported in the case of indomethacin, the physical
stability of the amorphous material obtained via milling of the
crystalline solid differs significantly from that prepared through
a rapid cooling of a molten sample. In the recalled case, the
cryomilled material recrystallized over 1000 times faster than
the one obtained by vitrification.27,37 Even though throughout
the dielectric measurements, neither of the samples exhibited
any tendency toward recrystallization, we made an attempt to
determine the long-term physical stability of the samples.
In recent years, a number of reports suggested that the
recrystallization of the sample at temperatures below its Tg
depends on the sample’s global mobility. It has been
demonstrated on the examples of several amorphous APIs,
such as bicalutamide,68 ezetimibe,69 and griseofulvin,70 that the
recrystallization’s timescale is of the same order of magnitude
as the value of τα in the glassy state. Therefore, one might be
able to predict the approximate long-term physical stability of a
given amorphous API, based only on the τα predicted for
temperatures below its Tg.
There is a method allowing the determination of structural
relaxation times deeply in the glassy state, which is based on
the construction of the so-called master curve.71 To obtain
such a plot, one has to horizontally shift α-loss peaks obtained
at a certain temperature, higher than Tg, to a glassy region,
where the α-process is too slow to be experimentally observed
(see red and blue dotted lines in Figure 5A,B, respectively).
The detailed illustration of this procedure is presented in
Figure S6 in the Supporting Information. It should be pointed
out that the “master curve” method can be employed only in
cases when the shape of the α-process does not change with
the increasing temperature, which actually is true in the case of
the investigated samples. The performed analysis allowed us to
predict the temperature behavior of α-relaxation times in the
Figure 5. (A, B) Representative dielectric loss spectra of amorphous BOS. Light red lines correspond to the vitrified sample, while light blue lines
correspond to the cryomilled one. Dotted lines indicate the so-called master plot method. (C) Relaxation map of BOS. Red and blue pentagons
correspond to the vitrified and cryomilled samples. The red and blue empty pentagons represent the τα values predicted from so-called master plot
method for the vitrified and cryomilled API, respectively. The temperature dependence of τα in the supercooled liquid has been described by the
VFT equation and extrapolated to lower temperatures that correspond to the glassy state (gray solid lines).
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disordered state of vitrified and cryoground BOS (see Figure
5C).
Interestingly, the obtained results indicated that at T < Tg,
the cryomilled BOS is characterized by longer relaxation times
than in the case of the vitrified one. More importantly, the
τα(T) of the amorphous sample prepared by cryomilling
follows the VFT equation (eq 4) describing the temperature
evolution of the structural relaxation above Tg, extrapolated to
the amorphous region (see the gray line in Figure 5C). Based
on the presented data, it is evident that the cryomilled API
shows slower mobility/longer relaxation time below the Tg (it
may suggest higher physical stability) and therefore appears
more “aged” or has lower free energy compared to the melt-
quenched sample. This was also evident from the extent of
enthalpy recovery in DSC thermograms shown in Figure 2a.
As a final point, we decided to check whether there are
differences between dissolution rates of both amorphous BOS
samples with respect to the crystalline form of the drug. As
mentioned in the Introduction section, BOS (a week acid, BCS
class IIa drug) is poorly soluble in water but highly permeable
through biological membranes. Its bioavailability after oral
administration is around 50%.72 Increasing the BOS
dissolution rate through amorphization can increase the
absorption and efficacy of the API. We have performed
intrinsic dissolution tests in 1% w/v SDS medium recom-
mended by the Food and Drug Administration (FDA)
Dissolution Database. The results of these studies are
presented in Figure 6. As expected, the crystalline form of
API exhibited a slower dissolution rate from the beginning of
the test than its amorphous counterparts. On the other hand,
the dissolution behavior of amorphous systems was quite
different. Initially, the vitrified BOS dissolution profile showed
a 12-fold higher intrinsic dissolution rate of API (IDR = 0.192
± 0.029 mg min−1 cm−2) than pure crystalline substance (IDR
= 0.016 ± 0.004 mg min−1 cm−2). On the other hand,
cryomilled BOS revealed rather unusual behavior, i.e., it has
IDR (0.043 ± 0.008 mg min−1 cm−2) only 2.7-fold higher than
the crystalline one. The higher free energy of amorphous
materials is generally associated with increased solubility and
dissolution rates. Taking into account the results of thermal
and dielectric studies, one can correlate the observed
differences in dissolution profiles of both amorphous samples
(during the first 15 min of the test) with their physical
properties. As shown before, the cryoground BOS is more aged
and probably more physically stable compared to the vitrified
sample. That might explain its lower IDR (slower dissolution
rate), only slightly higher (faster) with respect to the crystalline
form of API.
Interestingly, after 40−60 min of the test, both amorphous
materials changed their dissolution kinetics significantly, and
their dissolution rate after 60 min was similar to that for
crystalline substance. Such behavior in an aqueous environ-
ment, and almost identical IDR values as the crystalline form,
may indicate the conversion of amorphous forms back to the
crystalline monohydrate. Importantly, such a solvent-mediated
phase transformation of anhydrous APIs has also been
reported by other authors73−78 (BOS molecule has a high
value of a solvent-accessible surface area,55 and this property
may cause a quick phase conversion). However, it should be
noted that the extent of dissolution is still considerably higher
in the melt-quenched sample and is not drastically decreased.
This does indicate that the rate of conversion to the crystalline
form in the vitrified sample is slower compared to the
dissolution of the amorphous API in the medium.
■ CONCLUSIONS
In the present study, amorphous BOS obtained by two
methods, vitrification and cryomilling, was thoroughly
characterized. X-ray diffraction and infrared spectroscopy
examinations showed that both disordered samples are very
similar in terms of the local structure and H-bonding scheme.
Dielectric studies revealed that they are also characterized by
the same shape of the structural (α)-peak as well as molecular
dynamics at T > Tg. Moreover, the analysis of temperature
dependence of α-relaxation times (predicted for both samples
at T < Tg from the master curve analysis), like the results of
calorimetric measurements, indicated that cryoground BOS is
more aged and probably more physically stable compared to
the vitrified API. Importantly, the differences in physical
properties of both amorphous systems influenced their
Figure 6. Mean intrinsic dissolution profiles (n = 3) of crystalline, vitrified, and cryomilled bosentan (BOS) in 1% w/v aqueous solution of sodium
dodecyl sulfate. The intrinsic dissolution rate (IDR) was calculated from each curve’s slope for periods of 0−120 min for crystalline BOS, and 0−15
and 60−120 min for vitrified and cryomilled BOS, respectively (see the text).
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dissolution rates in 1% w/v aqueous solution of sodium
dodecyl sulfate (IDR of the quenched sample at first 15 min of
the test was clearly higher with respect to the cryomilled one).
Furthermore, FTIR data, together with the results of the TGA
method clearly showed that cryomilling leads to the formation
of nearly anhydrous amorphous BOS. This finding is different
from that reported by Megarry et al.56 (the authors obtained
hydrated disordered TRE during the mechanical treatment of
this saccharide). To explain the discrepancy between our
results and those presented in the paper,56 we considered the
difference in the chemical structure of TRE (hydrophilic
system) and BOS (hydrophobic system), as well as the type of
vessel used for milling of the sample. We hypothesize that in
the hermetically closed vessel, that is cooled from T = 298 to
80 K, there is a strong decrease in pressure. This fact together
with the release of the water from the crystalline lattice of BOS
hydrate generates conditions mimicking the ones applied
during freeze-drying. Therefore, water removal proceeds via
the sublimation of ice at very low temperatures and pressures.
In the mills, where the vessel is not hermetically closed, such
an effect is not detected. We think that the results presented
herein will initiate an interesting discussion on the behavior of
milled/cryomilled drug substances and the mechanism of
amorphization behind this experimental technique.
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